Mystery Chinese Investor closes deal with Mystery Company Cytori
Cytori investors were pleasantly surprised shortly before the third quarter call with an announcement that Lorem Vascular- Headquartered in Beijing, with offices in Hong Kong, Kuala Lumpur, Singapore, and Melbourne, according to the announcement- but according to the 8-K a Company organized under the laws of Australia closed a Common Stock Purchase Agreement, but what has more of my interest, both parties also..
entered into a License and Supply Agreement whereby Cytori exclusively licensed Lorem all rights to market and sell the Company Products for all Markets within the countries of China, Hong Kong, Australia, Malaysia and Singapore, excluding only the Cosmetic Market and the rights for Alopecia (hair loss). The term of the agreement is thirty years. Lorem Vascular will pay us license fees on its gross revenues up to a maximum amount of $500 million dollars in license fees. The license fees are payable over time based upon Lorem Vascular's achievement of gross revenue milestones in the amount of $50 million. At each such milestone, Lorem shall pay us a license fee of $10 million until the maximum payable license fees are reached.
As a part of the License and Supply Agreement, we have also agreed to supply Lorem with all of their requirements for our products based on fixed product transfer pricing. Lorem has agreed to purchase eight (8) Celution Devices and four hundred (400) consumable sets promptly after execution of the License and Supply Agreement, and to purchase an additional twenty three (23) Celution Devices and one thousand one hundred (1,100) Consumable Sets promptly upon receipt of regulatory approval in China.
Does the development and role-out of DISRUPTIVE POC technology require unorthodox methods and Mr. Lim´s?
It sure seems like it- doesnt it? Cytori investors have been waiting more than 6 years on the promised therapeutic application development deal that Cytori CEO Chris Calhoun started to promise in November 2006.
It still is not there, since Cytori Cell Therapy is likely to wipe out substantial "pills revenue"i.e. is extremely disruptive by any strech of the imagination- but Mr. Lim, without pharmaceutical interests burdening him, is there and apparently loads of clinical data are coming our way from translational efforts, which the last image starts to imply also.
For US investors and ANALYSTS (Kolbert & Co) - why don´t you finally wake up and start asking some sensible questions and put some fire under the "behinds" of Cytori management and ask where those EIGHT cardiac clinics are conducted- patients treated etc and also which studies (three as per last slide) are conducted by private investigators in the US??????????????
The future will be fun for investors in autologous POC apps and great for patients I believe
This world needs affordable and effective regen therapies and I think the JAPANESE WILL SHOW US THE WAY IN THE NEAR FUTURE.